|
|
Article: Addex Brings In CHF40M For CNS Product Studies.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
BioWorld International Correspondent
Addex Pharmaceuticals SA raised CHF40 million (US$31.9 million) in a Series C financing to fund Phase II trials of its lead compound, ADX10059, a negative allosteric modulator of metabotropic glutamate receptor 5 (mGluR5), in three different indications.
Two big pharma-backed venture capital funds joined the Geneva-based company's roster of investors. SR One, of West Conshohocken, Penn., the venture capital arm of London-based GlaxoSmithKline plc, led the round, while the Roche Venture Fund, backed by F. Hoffmann-La Roche Ltd., of Basel, Switzerland, also participated. Existing investors Sofinnova Partners, Index ...
Related newspaper, magazine, and journal articles:
|
|
Article: Addex Shareholders Elect Ray Hill to Board of Directors at the ...
CCNMatthews Newswire;
April 18, 2008 ;
700+ words
... ... seat effective May 1, 2008. Vincent Mutel, CEO, said: "I am pleased that Ray ... incorporation in 2002," said Vincent Mutel. Also during the AGM, Antoine Papiernik ... advanced drug candidate, ADX10059, a negative allosteric modulator (NAM) of metabotropic glutamate ...
|
|